Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001654954-23-009474
Filing Date
2023-07-20
Accepted
2023-07-20 16:15:37
Documents
4

Document Format Files

Seq Description Document Type Size
1 424B3 tenx_424b3.htm 424B3 25676
2 PRESS RELEASE tenx_ex991.htm EX-99.1 16841
3 tenx_ex991img2.jpg GRAPHIC 2888
4 tenx_424b3img2.jpg GRAPHIC 4510
  Complete submission text file 0001654954-23-009474.txt   54267
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-269363 | Film No.: 231099877
SIC: 2834 Pharmaceutical Preparations